СПИСОК ЛИТЕРАТУРЫ

1. Агеев Ф.Т, Фомин И.В., Мареев В.Ю., Беленков Ю.Н. Распространенность артериальной гипертонии в Европейской части Российской Федерации. Данные исследования ЭПОХА// Кардиология.

2. Бобров В.А. Системная артериальная гипертензия при хроническом обструктивном бронхите: современные взгляды и новые понимания/ В.А. Бобров, И.М. Фуштейн, В.И. Боброва// Клиническая медицина. 1995, №3, С.24

3. Бобров В.А., Фуштей И.М., Поливода С.Н; Состояние регионарной гемодинамики при хроническом обструктивном* бронхите с артериальной гипертензией. // Терапевтический архив. 1986; №58(12), С. 20-24

4. Бобров В.А., Фуштейн И.М., Боброва В.И. Системная артериальная гипертензия при хроническом обструктивном бронхите: современные взгляды и новые понимания. //Клиническая медицина. 1995, №3, С.24

5. Величковский Б.Т. Свободнорадикальное окисление как звено срочной и долговременной адаптации организма к факторам окружающей среды И Вестник РАМН. 2001, №5, С. 45-51

6. Владимиров Ю.А. Свободно-радикальное окисление липидов и физические свойства липидного бислоя биологических мембран// Биофизика. 1987, Т.32, №5, С.830-844

7. Волкова Л.И., Штейнгард Ю.Н. Легочная гипертензия при хроническом бронхите (патофизиология, диагностика, лечение и профилактика). Томск, Издательство Томского университета; 1992

8. Воронкова О.О. Состояние системы провоспалительных цитокинов и неспецифических маркеров воспаления у больных ХОБЛ и динамика их на фоне лечения // Автореферат диссертации на соискание ученой степени кандидата медицинских наук, Москва 2006 г.

9. Гаврилов В.Б., Мишкорудная М.И.. //Лабораторное дело. 1983, № 3,

С.33-35

10. Глезер Г.А., Глезер М.Г. Артериальная гипертония. - М.: Авиценна, ЮНИТИ, 1996,216 с.

11. Горбунов В.М. 24-часовое автоматическое мониторирование артериального давления.// Кардиология. -1997. -35 - №6.

12. Грацианский Н.А. Предупреждение обострений коронарной болезни сердца. Вмешательства с недоказанным клиническим эффектом: ингибиторы ангиотензин-превращающего фермента и антиоксиданты.// Кардиология. 1998, №38(6), С. 4-19

13. Егоршин В.Ф., Троцюк В.В. Состояние микроциркуляторного русла у

больных хроническими неспецифическими заболеваниями легких. //Терапевтический архив. 1978, №4(65), С.102-105 -

14. Жданов В.Ф. Клинико-статистическая характеристика больных

неспецифическими заболеваниями легких с системной артериальной гипертензией. //«Актуальные проблемы пульмонологии»., сб. науч. тр., Л., 1991, С.89-93- ,

15. Жданов В.Ф. Системная артериальная гипертензия у больных бронхиальной астмой. //Автореф. дисс. д-ра мед. наук., СПб., 1993

16. Жданов В.Ф., Амосов В.И., Синицина Т.М., Ярцева Е.Э. Особенности легочной микроциркуляции и функции внешнего дыхания у больных бронхиальной астмой с системной артериальной гипертензией. //Терапевтический архив. 1991, №10(63), С.144-146

17. Заволовская Л.И. Ремоделирование системы кровообращения и дыхания у больных хроническим обструктивным бронхитом. //Дисс. д-ра мед. наук, М., 1996, 276с

18. Задионченко В.С., Адашева Т.В., Погонченкова И.В. и др. Артериальная

гипертония у больных хроническими обструктивными болезнями легких: клинико-функциональные особенности, выбор терапии.

Кардиоваскулярная терапия и профилактика. 2004, (3):33, С. 42

19. Задионченко В.С., Адашева Т.В., Шилова Е.В. и соавт. Клинико­функциональные особенности артериальной гипертонии у больных хроническими обструктивными болезнями легких. РМЖ, 2003, №9,С. 535-538

20. Задионченко В.С., Волкова Н.В., Свиридов А.А., Копалова С.М. Системная и вторичная легочная артериальная гипертония. //Российский кардиологический журнал. 1997, №6, С.28-37

21. Зборовская И. А., Банникова М. В. Антиоксидантная система организма, её значение в метаболизме. Клинические аспекты //Вестник РАМН.

' 1995, № 6, С. 53-60

22. Зенков Н.К.

23. Зимин Ю.В. Некоторые критические точки оценки суточного профиля артериального давления при его мониторировании и их значение для выработки тактики лечения больных артериальной гипертензией. // Клинический вестник. 1996, №1, С. 30-32

24. Катюхин В.Н., Синицина Т.М. Влияние адекватной терапии на показатели функции внешнего дыхания у больных артериальной гипертензией в сочетании с обструктивными заболеваниями легких. //Терапевтический архив, 1990, №3(62), С.75-78

25. Кобалава Ж.Д., Терещенко С.Н., Калинкин А.Л. Суточное мониторирование артериального давления: методические аспекты и клиническое значение. 1997, С. 9-11,14-15

26. Корнев А.В., Коротаев А.Л., Калинин Н.Л. С-реактивный белок в клинике («НИКОКАРД» - новый метод для традиционного теста) Клиническая лабораторная диагностика, 1999, Леб, С.37-40

27. Кубышкин В.Ф., Солдатченко С.С., Беленький А.И. Гуморальные механизмы пульмонологической гипертензии. //Труды Крымского медицинского института, 1985, т. 108, С.50-52

28. Кубышкин В.Ф., Солдатченко С.С., Коновалов В.И. Особенности течения хронических обструктивных заболеваний легких в сочетании с системной артериальной гипертензией. //Терапевтический архив. 1985, №2(57), С.114-116

29. Кузьмичева Н.В. Антагонисты кальция в лечение артериальной гипертонии у больных с хроническим бронхообструктивным синдромом. //Дис. канд. мед. наук. М., 1999. 166 с.

30. Кулинский В.И. Активные формы кислорода и окси дативная модификация макромолекул: польза, вред и защита// Соросовский образовательный журнал, 1999, № 1, С. 2-7

31. Куценко С.А. Основы токсикологии //Том 4, 2002 г. Санкт-Петербург СТР. 119

32. Ланкин В.З. Метаболизм липоперекисей в тканях млекопитающих. Биохимия липидов и их роль в обмене веществ. М.: Наука, 1981 ;С. 75-95

33. Леденев А.Н., Руге Э.К. Генерация супероксидных радикалов митохондриями сердца в условиях ишемии.

34. Ленинджер А. Биохимия. Молекулярные основы структуры и функции клетки. М.: «Мир», 1999, С.390-422

35. Маянский Д.Н., Цырендоржиев Д.Д. Активация макрофагов. // Успехи современной биологии. 1990, Т. 109, Вып. З, С. 352-369

36. Меньшикова Е.В., Зенков Н.К., Шергин С.М. Биохимия окислительного стресса. Оксиданты и антиоксиданты. Новосибирск: Изд-во СО РАМН,1994, С.58-77

37. Меньшикова Е.В., Зенков Н.Н. Антиоксиданты и ингибиторы радикальных окислительных процессов //Успехи современ. биологии. 1993,Т. 113, №4, С. 442-453

38. Мухамеджанова Г.Ф. Влияние антигипертензивных и антиангинальных препаратов на органы дыхания. //Кардиология, 1995, №3(35), С.94-95

39. Мухарлямов Н.М. Легочное сердце. В кн.: Руководство по кардиологии. Т. 3: Болезни сердца. Е.И. Чазов (ред.). М., Медицина; 1992. С. 230—80

40. Мухарлямов Н.М., Саттбеков Ж.С., Сучков В.В. Системная артериальная гипертензия у больных хроническими неспецифическими заболеваниями легких. //Кардиология, 1974, №12(34), С.55-61

41. Ольбинская Л.И., Цветкова О.А., Воронкова О.О.. Исследование активности провоспалительных цитокинов у больных ХОБЛ. В книге: «Актуальные вопросы внутренней медицины», Издательский дом «Русский врач» М. 2003г., с. 198-205

42. Профилактика, диагностика и лечение артериальной гипертонии. Российские рекомендации (второй пересмотр) / Разработаны* Комитетом Всероссийского научного общества кардиологов // Приложение к журналу Кардиоваскулярная терапия и профилактика. Москва, 2004.

43. Серебрякова В.И. Клинико-патологические особенности

нейроэндокринной регуляции при сочетании артериальной гипертензии с лабильной и стабильной обструкции бронхов в возрастном и половом аспекте, коррекция выявленных нарушений. //Авт. дисс. д-ра. мед. наук., СПб, 1998,55 с.

44. Серебрякова В.И., Литвинов А.С., Михайлов А.М. Состояние центральной и периферической адренергической активности при сочетании бронхиальной астмы и артериальной гипертензии.

45. Сидоренко Б. А., Преображенский Д. В., Соплевенко А. В., Иванова Н. А., Стеценко Т. М. Кондесартан - новый блокатор АТ 1- ангиотензиновых рецепторов: особенности фармакологии и опыт использования при артериальной гипертензии. // Кардиология. 2004, №1, С.55-65

46. Соодаева С.К. Роль свободнорадикального окисления в патогенезе ХОБЛ // Атмосфера. 2002, №2, С.24-25

47. Ткаченко Б.И. Венозное кровообращение. //Москва, 1979, 222 с.

48. Федорова Т.А., Химочко Т.Г., Ройтман А.П. и др. К вопросу о состоянии ренин-ангиотензин-альдостероновой системы у больных хроническими обструктивными болезнями легких с легочным сердцем. //Московский медицинский журнал, 2001, №1, С.23-25

49. Холодкова Н.Б. Эндотелиальная дисфункция и её коррекция антагонистами рецепторов ангиотензина II у больных хроническим легочным сердцем //Диссертация на соискание ученой степени канд. мед. Наук. Москва, 2006

50. Цветкова О.А., Воронкова О.О. Динамика провоспалительных цитокинов ИЛ-6 и ФНО-а в сравнении с неспецифическими маркерами воспаления у больных ХОБЛ на фоне терапии р₂^—агонистами длительного действия. // XI Всероссийский конгресс «Человек и лекарство». Сборник тезисов. Москва, 2004, С. 278

51. Чернух А.М., Александров П.Н., Алексеев О.В. Микроциркуляция. //«Медицина», М., 1984, С. 432

52. Ярема Н.И., Коновалова Г.Г., Ланкин В.З. Изменение активности антиоксидантных ферментов у больных гипертонической болезнью. Кардиология, 1992, №32(3), С. 46-48

53. Ярема Н.И., Рудык Б.И. Липопротеиды и перекисное окисление липидов при гипертонической болезни и проведении гипотензивной терапии. Тер. Архив. 1991, №8, С. 144-146

54. Albelda SM. Endothelial and epithelial cell adhesion molecules. Am J Respir Cell Mol Biol 1991; 4:195-203

55. Albrecht H.P., Hiller D.,Muck-Weymann M et al. Dynamic function tests for detection of physiologic and pathophysiologic reactions in cutaneous microcirculation.//Hautarzt., 1995; 46(7): 455-461

56.

57. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9

58. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80

59. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001; 19:857— 861

60. Bearpark H, Elliott L, Grunstein R, Cullen S, Schneider H, et al. Snoring and sleep apnea. A population study in Australian men: Am J Respir Crit Care Med 1995;151: 1459-65

61. Beatrice Beck-Schimmer, Ralph C. Schimmer, Caveh Madjdpour, John M. Bonvini, Thomas Pasch, and Peter A. Ward Hypoxia Mediates Increased Neutrophil and Macrophage Adhesiveness to Alveolar Epithelial Cells/ Am. J. Respir. Cell Mol. Biol. 2001; 25(6):780-787

62. Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R. Amlodipine increases endothelial nitric oxide by dual mechanismus. Pharmacology 2004; 70:39-45

63. Berkenboom G, Langer I, Carpentier Y, et al. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: a bradykinin- dependent mechanism. Hypertension 1997;30(3 Pt l):371-76

64. Berry C, Brosnan MJ, Fennell J, et al: Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens 2001;10:247-255

65. Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Leiby BE, Vela-Bueno A, et al. Association of hypertension and sleep-disordered breathing: Arch of Intern Med 2000; 160: 2289-95

66. Bonner G., Preis S., Schunck U et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. //J Cardiovasc Pharmacol. 1990; 15 (16):46-56

67. Boulanger C., Vanhoutte P.M. The role of the endothelium in the regulation of vasomotor activity. Arch. Mai. Coeur. Vaiss. 1991; 84(l):35-44

68. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006;61:17-22

69. Brooks D, Homer RL, Kozar LF, Render-Teixeira CL, Phillipson EA. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J Clin Invest 1997;99:106-9

70. Brouwer RML, Bolli P, Eme P, et al. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol. 1985;7:288-291

71. Buist A.S., Vollmer W.M. Smoking and other risk factors. —• In: Murray J.F., Nadel J.A., eds. Textbook of respiratory medicine. Philadelphia: W.B. Saunders. 1994; 1259-1287

72. Cadrillo C, Kilcoyne CM, Quyyumi A, et al. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in essential hypertension. Circulation. 1998; 97: 851-856

73. Cai H & Harrison DG Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 10, 840-844

74. Caldwell PRB, Seegal BC, Hsu КС, Das M & Soffer RL Angiotensin­converting enzyme: vascular endothelial localization. Science 1976; 191: 1050-1051

75. Campbell DJ Circulating and tissue angiotensin systems. Journal of Clinical Investigation 1987; 79:1-6

76. Carl J. Pepine, David S. Celermajer, Helmut Drexler. Vascular health as a therapeutic tagert in cardiovascular disease. // University of Florida. 1998; 40

77. Ceriello A, Failed E, Motz E, Taboga C, Tonutti L, Ezsol Z, Gonano F, Bartoli E Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998;30:146— 149

78. Chaieb JA, Fasolo P, Ruschel SP, et al. Aspectos epidemiologicos e tabagismo em Porto Alegre: prevalencia do tabagismo e DPOC. J Pneumol 1995;21:171-179

79. Chang LY, Kang BH, Slot JW,-Vincent R, Crapo JD. Immunocytochemical localization of the sites of superoxide dismutase induction by hyperoxia in rat lungs. Lab Invest 1995; 73: 29-39

80. Chen J., Radford M.J., Wang Y. et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001;37:1950-1956

81. Chen, YF, and Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 2000; 320: 223-232

82. Clapp BR, Hirschfield GM, Storry C, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005; 111:1530-6

83. Clozel M, Kuhn H, Hefti F, et al. Endothelial dysfunction and subendothelial

monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension 199 Г; 18:132-41 •

84. Cominacini L, Garbin U, Fratta Pacini A, et al. Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens 1997;15:1633-40

85. Cominacini L, Pasini AF, Pastorino AM, et al. Comparative effects of different dihydropyridines on the expression of adhession molecules induced by TNF-alphaon endothelial cells. J Hypertens 1999;17:1837-41

86. Cooke JP The endothelium: a new target for therapy. Vase Med 2000; 5:49­53

87. Coursin DB, Cihla HP, Oberley TD, Oberley LW. Immunolocalization of antioxidant enzymes and isozymes of glutathione S-transferase in normal rat lung. Am J Physiol 1992; 263: L679-L691

88. Crapo JD, Oury T, Rabouille C, Slot JW, Chang LY. Copper,.zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc Nath Acad Sci USA 1992; 9: 10405-10409

89. Cruickshank JM, Lewes J, Moore EV, Dodd C. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens 1992; 17: 85-90

90. Dablof B, Sever PS, Poulter NR, for the ASCOT investigators. 2005; 366: 895-906

91. Daga Mj Chhabra R, Sharma В Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. J Biosci 2003; 28:7—11

92. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - A metanalysis of 109 treatment studies? Am J Hypertens 1992; 5: 95-110

93i Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys: MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397

94. Dart R.A., Gollub S., Lazar J. et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest 2003;123:222—43

95. David M. Pollock Endothelin, Angiotensin, and Oxidative Stress in Hypertension Hypertension. 2005 ;45:477

96. Dekhuijzen PN, Aben KK, Dekker I, Aarts LP, Wielders PL, Van Herwaarden CL, Bast A: Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;1'54: 813-816

97. Dentener MA, Creutzberg EC, Schols AM, et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001; 56:721-726

98; Depre C., Wijns W., Rjbert A. et al. Pathology of unstable plaque: correlation with the clinical severity of acute coronary syndromes // J. Amer. Coll. Cardiology. 1997; 30: 694-702

99. Desideri G, Ferri C, Bellini C, et al. Effects of ACE inhibition on spontaneous and insulin-stimulated endothelin-1 secretion: in vitro and in vivo studies. Diabetes 1997;46:81-86

100. Ding, Y., Vaziri, N. D. Nifedipine and Diltiazem but Not Verapamil Up- Regulate Endothelial Nitric-Oxide Synthase Expression. J. Pharmacol. Exp. Then, 2000; 292: 606-609

101. Dinh-Xuan A.T., Higenbottam T.W., Clelland G.A. et ah Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl Med J 1991;324:1539—47

102. Dohi Y, Criscione L, Pfeiffer K, Luscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistence arteries. //J. Cardiovasc Pharmacol; 1994;; 24: 372-379

103. Dong Q., Wright J;R. Expression of C-reactive protein by alveolar macrophages J. Immunology. 1996; 156: 4815-4820

104. Doroshow J.H. Toxicol. Lett. 1995; 82-83:395 -398

105. Droge W . Free radicals in the physiological control of cell function. Physiol

Rev 2002; 1,47-95 .

106. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W: Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005; 60: 293-300

107. Durmowicz A.G., Stenmark K.R. Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr Rev 1999;20:e91—el02

108. Dutnie GG, Arthur JR, James WP: Effects of smoking and vitamin E on blood antioxidant status. Am J ClinNutr 1991; 53: 1061-1063

109. Ellerbeck E.E., Jencks S.F., Radford M.J., Kresowik T.F., Craig A.S., Gold J.A., et al. Quality of care for Medicare patients with acute myocardial

infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-14

110. European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertention J. Hypertens. 2003; 21: 1011-1053

111. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000; 102:1000-1006

112. Figueras M., Brosa M., Gisbert R. Et coste de la enfermedad pulmonar obstructiva cronica en Espana//Rev. Esp. Farmacoeconomia, 1996; 5 (II): 33­43

113. Frei B., Stocker R., Ames B.N. Small molecule antioxidants defens in human extracellular fluids. In: Scandalios, J.G., ed. Molecular biology of free scavenging systems. Cold Spring Harbor Laboratory Press. 1992:23-45

114. Fridovich I. Superoxide radical and superoxide dismutases. Annual Review of Biochemistry. 1995; 64: 97-112

115. Gan WQ, Man SFP, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005;127:558-564

116. Gardiner SM., Compton AM., Bennet T., Palmer RMJ., Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension, 1990; 15:486-492

117. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21

118. Gilks CB, Price K, Wright JL, Churg A. Antioxidant gene expression in rat lung after exposure to cigarette smoke. Am J Pathol 1998; 152: 269-278

119. Goldszer RC, Lilly LS, Solomon HS. Prevalence of cough during angiotensin converting enzyme inhibitor therapy. Am J Med 1988; 85:887

120. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blocade on mortality in high-risk and low - risk patients after myocardial infarction. N Engl J Med 1998;339:489-97

121. Griengling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity incultured vascular smooth muscle cells. Circ. Res. 1994; 74: 1141-1148

122. Guillermo Zalba; Gorka San Jose; Maria U. Moreno; Maria A. Fortuno; Ana Fortuno; Francisco J. Beaumont; Javier Diez Oxidative Stress in Arterial Hypertension Hypertension. 2001 ;38:1395

123. Guo X, Liu WL, Chen LW, Guo ZG: High glucose impairs endothelium- dependent relaxation in rabbit aorta. Acta Pharmacol Sin 2000; 21:169-173

124. Gust R., Schuster D. P. Vascular remodeling in experimentally induced subacute canine pulmonary hypertension// Experimental Lung Research - 2001;27:1-12

125. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? a multiple cause coding analysis. Eur Respir J 2003; 22: 809-14

126. Harry A.J. Struijker Boudier, Giuseppe Ambrosio (ed.) Microcirculation and cardiovascular disease // Lippincoott Williams & Wilkins. - 2000; 179

127. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-5

128. Homig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation., 1997;95:1115-1118

129. Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634-9

130. Hultin M. Fibrinogen and factor VII as risk factors in vascular disease. Prog. Hemost. Thromb. 1991; 10: 215-241

131. Hunninghake D.B. Cardiovascular Disease in Chronic Obstructive Pulmonary Disease The Proceedings of the American Thoracic Society 2005;2:44-49

132.1kuta T., Okubo H., Ishibashi H. et al. Human lymphocytes synthesize C- reactive protein. Inflammation. 1986; 10: 223-232

ІЗЗ.Ітаі Y., Hozawa A., Ohkubo T. et al. Predictive values of automated blood- pressure measurement: what can we learn from the Japanese population — the Ohasama study. Blood Pressure Monitoring. 2001; 6(6): 335-339

134.1ncalzi A.R., Fuso L., De Rosa M. Et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-800

135. Jameson M., Dai F.X., Luster T., Skopec J., Diederich A., Diederich D. Endothelium derived contracting factors in resistance arteries of young spontaneously hypertensive rats before development of overt hypertension. Hypertension, 1993, 21: 280-288

136. Jansson J., Nilsson T., Johnsson O. Von Willebrand factor in plasma: a novel risk factor for fecurrent myocardial infarction and death. Brit. Heart J. - 1991; 66: 351-355

137. Jeffery, PK Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53,129-136

138. JNC 7 Express. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program. NIH Publication No. 03-5233. May 2003

139. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348: 567-72

140. Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham Study. Am Heart J 1983; 105:311­315

141. Kessler R, Faller M, Fourgaut G et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 158-64

142. Kinnula V, Crapo J Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 2003; 167:1600—1619

143. Kocyigit A, Erel O, Gur S Effects of tobacco smoking on plasma selenium, zinc, copper and iron concentrations and related antioxidative enzyme activities. ClinBiochem 2001; 34:629-633

144. Koenig W. Atherosclerosis involves more than just lipids: focus on inflammation. Eur. Heart J. 1999; 1:19-26

145. Kony S, Zureik M, Driss F, Neukirch C, Leynaert B, Neukirch F. Association

of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax 2004;59:892-896 -

146. Koren MJ, Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension Ann Intern Med 1991; 114: 345-52

147. Krumholz HM' Larson M, Levy D. Prognosis of left vernacular geometric patterns in Framingham Heart Study. J Am Coll Cardiol 1995; 25: 884-97

148. Kumar K.W., Das U.M. Are free radicals involved in the pathobiology of human essential hypertension? Free Rad.Res.Commun. 1993,19: 59-66

149. Kurys E, Kurys P, Kuzniar A Analysis of antioxidant enzyme activity and magnesium level in chronic obstructive pulmonary disease. Ann Univ Mariae Curie Sklodowska 2001; 56:261-266

150. Lacourciere Y, Lefebvre J, Nakhle G, et al. Association between cough and angiotensin converting enzyme inhibitors vs angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 1994; 12:S49-S53

151. Laursen J.B., Rajagopalan S., Galis Z., Tarpey M., Freeman B.A., Harrison

D. G. Role of superoxide in angiotensin Il-indused but not catecholamine- indused hypertension. Circulation, 1997, 95: 588-593

152. Lin M, Yang YF, Lee D, et al. Comparisons of long-term effects of lisinopril vs nifedipine vs conventional therapy in the treatment of mild-to-moderate hypertension in patients with chronic obstructive pulmonary disease. Chinese Med J 1996; 57:392-400

153. Linden M, Rasmussen JB, Piitulainen E, Tunek A, Larson M, Tegner H, Venge P, Laitinen LA, Brattsand R: Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis 1993; 148: 1226-1232

154. Lissi E., Salim-Hanna M., Pascual C., Castillo M. Evaluation of total antioxidant potential (TRAP) and total antioxidant reactivity from luminal- enhanced chemiluminescence measurements. Free Rad. Biol. & Med.; 1995; 18(2): 153-158

155. Liuzzo G., Biasucci L.M., Gallimore J.R. et al. The prognostic value of C-

reactive protein and serum amiloid A protein in patients with severe unstable angina. New Engl. J. Med. 1994; 331:417-424 ~

156. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;1:2056-69

157. Lucher T.F., Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator Atherosclerosis. 1995; 118: S81-90

158. Luscher T.F. Endothelial control of vascular tone and growth. Clin. Exp. Hypertens., 1990; 12(5): 897-902

159. MacNee W., Rahman I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S58—S65

160. MacNee W: Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 50-60, 2005

161. Man SFP, Sin DD. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:78-82

162. Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993. Am J Respir Crit Care Med 1997; 156: 814-8

163. Marklund SL. Human copper-containing superoxide dismutase of high molecular weight. ProcNatl Acad Sci USA 1982; 79: 7634-7638

164. Marshall RP, Gohlke P, Chambers RC, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286(1): 156-64

165. Marshall RP. The pulmonary renin-angiotensin system. Curr Pharm Des 2003; 9(9): 715-22

166. Mason RP, Mak IT, Trumbore MW, Mason PE. Antioxidant properties of calcium antagonists related to membrane biophysical interactions. Am J Cardiol 1999;84:16L-22L

167. McCusker К and Hoidal J Selective increase of antioxidant enzyme activity in the alveolar macrophages from cigarette smokers and smoke • exposed hamsters; Am. Rev. Respir. Dis. 1990; 141: 678-682

168. Meydani M Omega-3 fatty acids alter soluble markers of endotheliahfunction in coronary heart disease patients. Nutr Rev 2000; 58:56-59

169. Murray C.J.L., Lopes A. D. (ed.). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. — Cambridge, MA: Harvard University Press, 1996

170. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42

171. Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet 1997; 349: 1347-52

172. Nishikimi N., Rao N.A., Yagi K. Biochem. Biophys. Res. Commun., 1972; 46: 849-854

173. Nosratola D Vaziri, Bernardo Rodrfguez-Iturbe Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nature Clinical Practice Nephrology 2006; 2(10): 582-593

174. Padfield PL, Mortone JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. J Clin Endocrinol 1977; 74:251-259

175. Padmaja S., Huie R.E. The reaction of nitric oxide with organic peroxyl radicals. Biochem.Biophys.Res.Commun. 1993,195: 539-544

176. Paglia D.E, Valentine W.N. Studieson the quantitative & qualitative characterization of erythrocyte glutationperioxidase. S. Lab. Clin. Med. 1967; 70(l):158-167

177. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-

derived nitric oxide in the abnormal endothelium-dependent • vascular relaxation of patients with essentialhypertension. Circulation. 1993; 87: 468­474 '

178. Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:369-373

179. Pepine CJ, Handberg E, Cooper-De-Hoff et al. A Calcium Antagonist vs Non­Calcium Antagonist Hypertension Treatment Stratagy for Patients With Coronary Artery Disease. The International Verapamil-Trandolapril Study (INVEST ): A Randomized Controlled Trial. JAMA 2003; 290 (21): 2805-16

180. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-1812

181. Peter W. F. Wilson, MD; Byung-Ho Nam, PhD; Michael Pencina, PhD; Ralph B. D’Agostino Sr, PhD; Emelia J. Benjamin, MD, MS; Christopher J. O’Donnell, MD, MPH С-Reactive Protein and Risk of Cardiovascular Disease in Men and Women From the Framingham Heart Study Arch Intern Med. 2005;165:2473-2478

182. Pontiroli AE, Pizzocri P, Koprivec D, Vedani P, Marchi M, Arcelloni C, Paroni R, Esposito K, Giugliano D Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin- 1 in humans. Eur J Endocrinol 2004;150:195-200

183. Rahman I, Li XY, Donaldson K, Harrison DJ, MacNee W. Glutathione homeostasis in alveolar epithelial cells in vitro and lung in vivo under oxidative stress. Am J Physiol 1995; 269: L285-L292

184. Rahman I, Macnee W: Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000;16: 534- 554

185. Rahman I, Morrison D, Donaldson К Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996; 154:1055-1060

186. Rahman I, Swarska E, Henry M Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease? Thorax 2000; 55:189-193

187. Repine J.E., Bast A., Lankhorst L. Oxidative stress in chronic obstructive pulmonary disease//Amer J Respir Crit Care Med, 1997; 156: 341-57

188. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction Circulation. 1998; 97: 2007-2011

189. Ridker PM, Haughie P Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med 1998; 46:391-395

190. Ridker PM, Hennekens CH, Buring JE, Rifai N C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843

191. Riise GC, Larsson S, Lofdalh GG, Andersson BA. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur Respir J 1994; 7:1673-7

192. Riska H, Sovijarvi ARA, Ahonen A, et al. Effects of captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma. J Cardiovasc Pharmacol 1990; 15:57-61

193. Rosengren A, Wilhelmsen L. Respiratory symptoms and long-term risk of death from cardiovascular disease, cancer and other causes in Swedish men. Int J Epidemiol 1998; 27: 962- 9

194. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340:115-126

195. Rubanyi GM, Kauser K, Gruser T. Effect of cilazapril and indomethacin on endothelial dysfunction in the aortas of spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 22(5): 23-30

196. Salpeter S. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respiratory Medicine, Volume 97, Issue 10, Pages 1094-1101

197. Savage D.D., Garrison R.J., Kannel W.B., Levy D., Anderson S.J., Strokes

J.III, Feinleib M., Castelli W.P.: The spectrum of left ventricular hypertrophy in general population sample: The Framingham Study. Circulation 1987; 75 (l):l-26 -

198. Schiffrin E.L. The endothelium of resistance arteries: physiology and role in hypertension. //Prostaglandins. Leukot. Essent. Fatty. Acids., 1996; 54(1): 17­25

199. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996;51:819-824

200. Sheiban I, Arcaro G, Covi G, Accardi R, Zenorini C. Lechi A. Regression of cardiac hypertrophy after antihypertensive therapy with nifedipine and captopril. J Cardiovasc Pharmacol 1987;10(10):S187-91

201. Shimokawa H. Endothelial dysfunction in hypertension. //J. Atheroscler. Thromb., 1998; 4(3):118-127

202. Simon A, Castro A, Kaski JC Assessment of endothelial dysfunction and its clinical usefulness. Rev Esp Cardiol, 2001; 54(2):211-217

203. Sin D. D., Man S. F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease // Circulation. —2003; 107: 1514—1519

204. Sin D.D., Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-997

205.Sohn H.Y., Raff u., Hoffman A. Et al. Differential role of angiotensin II receptor subtypes on endothelial 02- formation // Br. J. Pharmacol.- 2000; 131:667-672

206. Springer TA Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-314

207. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated • systolic hypertension. The Systolic Hypertension in Europe (SYST-EUR) trial investigators. Lancet 1997; 350:757-764

208. T.J. International comparisons in COPD mortality .//Am. Rev. Respir. Dis., 1989; 140:27-43

209. Taddei S.; Virdis A.; Ghiadoni L.; Sudano I.; Salvetti A. Effects of Antihypertensive Drugs on Endothelial Dysfunction: Clinical Implications Drugs 2002 ; 62 (2): 265-284

210. Teppeman LJ, Dahan A. Acetazolamide and breathing: does a clinical dose alter peripheral and central CO(2) sensitivity? Am J Respir Crit Care Med 1999;160:1592-1597

211. Tnom T.J. International comparisons in COPD mortality .//Am. Rev. Respir. Dis., 1989; 140: 27-43

212. Touyz RM & Schiffrin EL Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004;122:339-352.

213. Toyokawa Takeshi, Osaki Hiromi, Nagai Yoshitaka, Nakajima Yasuhide Blood vessel wall extacellular SOD protects endothelium-dependent

vasodilation- under oxidative stress. Japanese: Journal of Clinical and’ Experimental Medicine 1999;76(11):212-2214

214. Tsukagoshi H; Shimizu Y, Iwamae S, Hisada T, Ishizuka K, Dobashi K, Mori M: Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline. Respir Med 2000; 94:584-588

215. Ulfendahl H.R., Aurell M. Renin-Angiotensin. Portland Press. London; 1998,

P.305 '

216. Van Der Meer IM, de Maat MP, Hak AE, Kiliaan AJ, Del Sol Al, van der Kuip DA, Nijhuis RL,. Hofman: A, Witteman JC. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke. 2002;33:2750-2755

217. Venugopaf SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C- reactive protein decreases eNOS expression* and bioactivity in human aortic endothelial cells. Circulation. 2002; 106:1439-1441

218. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukinr6 inhibition attenuate the proatherogenic effects of G-reactive protein. Circulation 2002;105:1890-6

219. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C- reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002; 106:913-919

220. Verma S, Wang CH, Li SH; et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production ^nd inhibits angiogenesis. Circulation 2002;106:913-9

221. Wayner D.D.M., Burton G.W., Ingold K.U., Locke S. Quantative measurement of total , peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. FEBS J. 1985; 187:33-37

222. Weisiger RA, Fridovich I. Mitochondrial superoxide simutase. Site of synthesis and intramitochondrial localization. J Biol Chem 1973;248: 4793­4796

223. Weisiger RA, Fridovich I. Superoxide dismutase. Organelle specificity. J Biol Chem 1973;248: 3582-3592

224. Weitzenblum E, Demedts M. Treatment of pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir Mon 1998;7:180-8

225. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002;161:233-242

226. Xu X., Wess S.T., Rijcken B., Schoten J.P. Smoking, changes in smoking habits and rate of decline in FEV,: new insight into gender differences//Eur. Respir. J., 1994; 7: 1056-1061

227. Yagi K., Komura S., Kojima H., Sun Q., Nagata N., Ohishi N., Nishikimi M. Biochem. Biophys. Res. Commun. 1996; 2:486 - 491

228. Yildiz L, Kayaoglu N, Aksoy H (2002) The changes of superoxide dismutase, catalase and glutathione peroxidase activities in erythrocytes of active and passive smokers. Clin Chem Lab Med 40(6):612-615

229. Zhou T, Zhou SH, Qi SS, Shen XQ, Zeng GF, Zhou HN. The, effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome.Clin Chim Acta 2006 (accessed ahead of print on PubMed).

230. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984; 2:581-587